Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VIA-3196 · 2 trials · 1 indication
Evaluation will start from predose (Day -1) until the follow-up visit (Day 21)
| Arm | Type | Description |
|---|---|---|
| VIA-3196 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Multiple, ascending dosing groups (cohorts) will be evaluated. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm |
| VIA-3196 | DRUG | Oral, daily dosing for 14 days |
Inclusion Criteria: * The subject must be willing and able to provide written informed consent. * Healthy, non-smoking, males and females between the ages of 18 and 55 years of age (inclusive). * If female, the subject is of non-child bearing potential (i.e., surgically \[bilateral oophorectomy, hy...
VIA-3196 is an investigational small molecule being studied for drug safety in healthy volunteers. It is currently in Phase 1 clinical development, with completed trials evaluating its safety profile. The drug is not approved and remains under investigation.
VIA-3196 is being developed by Madrigal Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker MDGL. The company is conducting Phase 1 clinical trials to evaluate the drug's safety in healthy subjects.
VIA-3196 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both focusing on drug safety in healthy volunteers. The drug is investigational and has not been approved for any use.
VIA-3196 has been evaluated in two completed Phase 1 trials. NCT01367873 was an ascending single-dose study in 72 healthy subjects, and NCT01519531 was an ascending multiple-dose study in 48 healthy subjects. Both trials were conducted in the United States.
VIA-3196 is the sole name used for this investigational small molecule in its clinical trials. No alternative names have been reported for the drug in the available trial information.